Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare diseases encompassing pancreatic (PanNETs) and ileal NETs (SINETs), characterized by heterogeneous somatostatin receptors (SSTRs) expression. Treatments for inoperable GEP-NETs are limited, and SSTR-targeted Peptide Receptor Radionuclide Therapy (PRRT) achieves variable responses. Prognostic biomarkers for the management of GEP-NET patients are required. 18F-FDG uptake is a prognostic indicator of aggressiveness in GEP-NETs. This study aims to identify circulating and measurable prognostic miRNAs associated with 18FFDG- PET/CT status, higher risk and lower response to PRRT.

Bocchini, M., Tazzari, M., Ravaioli, S., Piccinini, F., Foca, F., Tebaldi, M., et al. (2023). Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors. FRONTIERS IN ONCOLOGY, 13, 1-18 [10.3389/fonc.2023.1136331].

Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors

Bocchini, Martine;Piccinini, Filippo;Grassi, Ilaria;Paganelli, Giovanni
2023

Abstract

Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare diseases encompassing pancreatic (PanNETs) and ileal NETs (SINETs), characterized by heterogeneous somatostatin receptors (SSTRs) expression. Treatments for inoperable GEP-NETs are limited, and SSTR-targeted Peptide Receptor Radionuclide Therapy (PRRT) achieves variable responses. Prognostic biomarkers for the management of GEP-NET patients are required. 18F-FDG uptake is a prognostic indicator of aggressiveness in GEP-NETs. This study aims to identify circulating and measurable prognostic miRNAs associated with 18FFDG- PET/CT status, higher risk and lower response to PRRT.
2023
Bocchini, M., Tazzari, M., Ravaioli, S., Piccinini, F., Foca, F., Tebaldi, M., et al. (2023). Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors. FRONTIERS IN ONCOLOGY, 13, 1-18 [10.3389/fonc.2023.1136331].
Bocchini, Martine; Tazzari, Marcella; Ravaioli, Sara; Piccinini, Filippo; Foca, Flavia; Tebaldi, Michela; Nicolini, Fabio; Grassi, Ilaria; Severi, Ste...espandi
File in questo prodotto:
File Dimensione Formato  
0073_2023_FrontiersInOnc_Bocchini.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 5.6 MB
Formato Adobe PDF
5.6 MB Adobe PDF Visualizza/Apri
1136331.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 2.43 MB
Formato Zip File
2.43 MB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/926500
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 3
social impact